CHARACTERIZATION OF STERILE INTRAOCULAR INFLAMMATORY RESPONSES AFTER INTRAVITREAL BEVACIZUMAB INJECTION
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to determine the frequency and characteristics of sterile intraocular inflammation occurring after intravitreal bevacizumab (IVB) (Avastin, Genentech, South San Francisco, CA) injection and to analyze whether a repeat IVB or intravitreal ranibizumab (IVR) (Lucentis, Genentech) injection after an episode of postinjection inflammation elicits a repeat inflammatory reaction. METHODS: A retrospective case series evaluated 16,166 IVB injections administered between 2006 and 2008. Patients with postinjection inflammation were analyzed for the number of previous injections, time from prior injection to incident injection, presenting signs and symptoms, treatment, visual acuity, time from onset to resolution and recovery of vision, and whether repeat injection caused recurrent inflammation. RESULTS: The incidence of sterile intraocular inflammation after IVB injection resolving with topical antibiotics and steroids alone was 0.27% (44 of 16,166). The average number of prior IVB injections in the ipsilateral eye was 2.8 ± 0.4 with 10 cases occurring with first-time injections. The average time from injection to recovery of visual acuity was 53 ± 18 days, and from injection to resolution of inflammation was 37 ± 5 days. Thirty-six cases received subsequent IVB or intravitreal ranibizumab, and there were three episodes of recurrent inflammation with repeat IVB. The average follow-up was 17 ± 1 month. CONCLUSION: In most cases of sterile intraocular inflammation after IVB, visual acuity returned to baseline, and intraocular inflammation rarely recurred with repeat IVB or intravitreal ranibizumab.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, patients may theoretically be more prone to inflammation when breakdown of the blood-retina barrier occurs in certain conditions such as exudative AMD, compromising the immune privilege of the vitreous [44].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [44]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Structure-Immunogenicity Relationships of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617 · cited 3×
“A patient’s major histocompatibility complex genotype may also influence the propensity to develop an immune reaction against certain monoclonal antibodies.(10)”
BackgroundInfluentialFung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
FINTAK, D. R., SHAH, G. K., BLINDER, K. J., REGILLO, C. D., POLLACK, J., HEIER, J. S., HOLLANDS, H., & SHARMA, S. (2008) · Retina · doi:10.1097/iae.0b013e3181884fd2 · Cited by 214 · cited 5×
“After 1 episode of sterile intraocular inflammation after IVB, 48% of the cases received repeat IVB, and 48% received subsequent IVR.”
BackgroundInfluentialPilli, S., Kotsolis, A., Spaide, R. F., Slakter, J., Freund, K. B., Sorenson, J., Klancnik, J., & Cooney, M. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.036 · Cited by 181 · cited 1×
“intravitreal antibiotics without performing a culture to prove an infectious etiology.(4,5) Other cases of culturenegative endophthalmitis resolve without intravitreal antibiotics and represent sterile noninfectious inflammation; the reported incidence of these is 0.”
BackgroundBrooks, S. A. (2004) · Molecular Biotechnology · doi:10.1385/mb:28:3:241 · Cited by 165 · cited 1×
“Additionally, bevacizumab is synthesized in a Chinese hamster ovarian cell line, and because glycosylation is species-and cellspecific, recombinant glycoproteins such as bevacizumab may have immunogenic epitopes despite humanized amino acid sequences.(8,12) Foreign epitopes on the bevacizumab molecule can be presented…”
BackgroundIntravitreal Silicone Oil Droplets After Intravitreal Drug Injections
Bakri, S. J., & Ekdawi, N. S. (2008) · Retina · doi:10.1097/iae.0b013e31816c6868 · Cited by 128 · cited 1×
“Silicone oil droplets have been documented in the vitreous after IVB and IVR, but have not been associated with intraocular inflammation.(14)”
BackgroundWickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124 · cited 2×
“An antiidiotypic immune response should occur with increasing severity with each rechallenge.(7,15) However, in the 2 patients (patient 14 and patient 43) who developed recurrent inflammation after repeat IVB, the subsequent inflammatory reactions tended to be more vigorous, suggesting that in most patients, a specifi…”
BackgroundGeorgopoulos, M., Polak, K., Prager, F., Prunte, C., & Schmidt-Erfurth, U. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.138479 · Cited by 124 · cited 1×
“Additionally, bevacizumab is synthesized in a Chinese hamster ovarian cell line, and because glycosylation is species-and cellspecific, recombinant glycoproteins such as bevacizumab may have immunogenic epitopes despite humanized amino acid sequences.(8,12) Foreign epitopes on the bevacizumab molecule can be presented…”
BackgroundTherapeutic Anti-VEGF Antibodies
Lien, S., & Lowman, H. B. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_6 · Cited by 101 · cited 1×
“Bevacizumab is a humanized full-length mouse monoclonal antibody that contains both Fc and Fab fragments, whereas ranibizumab contains only an affinity-matured humanized mouse Fab fragment.(11) Additionally, bevacizumab is synthesized in a Chinese hamster ovarian cell line, and because glycosylation is species-and cel…”
BackgroundBacterial Contamination of Needle Points after Intravitreal Injection
Nentwich, M. M., Yactayo-Miranda, Y., Weimann, S., Fröhlich, S. J., Wolf, A., Kampik, A., & de Kaspar, H. M. (2009) · European Journal of Ophthalmology · doi:10.1177/112067210901900215 · Cited by 19
Foster, C. S., Monroe, J. G., Campbell, R. J., Kalpaxis, J., Wetzig, R. P., & Greene, M. I. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.8.2787 · Cited by 9 · cited 1×
“An antiidiotypic immune response should occur with increasing severity with each rechallenge.(7,15) However, in the 2 patients (patient 14 and patient 43) who developed recurrent inflammation after repeat IVB, the subsequent inflammatory reactions tended to be more vigorous, suggesting that in most patients, a specifi…”
Background
Cited by
Diagnostic and Therapeutic Challenges
Sadiq, M. A., Loh, G. K., Sepah, Y. J., Nguyen, Q. D., & Lin, P. (2015) · Retina · doi:10.1097/iae.0000000000000275 · Cited by 217
Zhao, Y., & Singh, R. P. (2018) · Drugs in Context · doi:10.7573/dic.212532 · Cited by 191
Endophthalmitis: state of the art
Schwartz, S., Vaziri, K., Kishor, K., & Flynn, Jr. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s76406 · Cited by 164
Where should siRNAs go: applicable organs for siRNA drugs
Ahn, I., Kang, C. S., & Han, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00998-y · Cited by 171
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Metadata
- Authors
- Chong, D. Y., Anand, R., Williams, P. D., Qureshi, J. A., & Callanan, D. G.
- Affiliations
- Texas Retina Associates (United States) (US)
- Venue
- Retina
- Published
- 2010-10
- Volume
- 30
- Issue
- 9
- Pages
- 1432-1440
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2036940508
- Cited by
- 66
- References
- 14
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 4
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- bevacizumab, intravitreal injection, ranibizumab, recurrent inflammation, anti-VEGF therapy, visual acuity recovery
- MeSH terms
- Bevacizumab, Aged, Antibodies, Monoclonal, Female, Humans, Macular Degeneration, Macular Edema, Male, Endophthalmitis, Postoperative Complications, Retrospective Studies, Time Factors, Visual Acuity, Incidence, Retreatment, Recovery of Function, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.